Management of intestinal involvement in systemic sclerosis

Journal of Clinical Rheumatology

Volumn 13, Issue 3, 2007, Pages 116-118

  Wollheim, Frank A ^a   Åkesson, Anita ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE; DOMPERIDONE; ERYTHROMYCIN; METOCLOPRAMIDE; OCTREOTIDE; PREPULSIDE; TEGASEROD; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CONSTIPATION; DIARRHEA; DYSPEPSIA; EDITORIAL; ENTEROPATHY; ESOPHAGUS DISEASE; EXTRAPYRAMIDAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; INTESTINAL DYSMOTILITY; INTESTINE PERFORATION; IRRITABLE COLON; MALABSORPTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSEUDOOBSTRUCTION; QT PROLONGATION; SYSTEMIC SCLEROSIS; VOMITING;

DOMPERIDONE; DOPAMINE ANTAGONISTS; GASTROINTESTINAL AGENTS; GASTROPARESIS; HUMANS; INDOLES; METOCLOPRAMIDE; OCTREOTIDE; SCLERODERMA, SYSTEMIC;

EID: 34250175518     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e3180645d3d     Document Type: Editorial

References (25)

1. Zawada ET Jr, Clements PJ, Furst DA, Bloomer HA, Paulus HE, Maxwell MH. Clinical course of patients with scleroderma renal crisis treated with captopril. Nephron. 1981;27:74-78.
2. Wollheim FA. ACE inhibitors could prevent long-term damage in systemic sclerosis patients experiencing scleroderma renal crisis. Clin Exp Rheumatol. 2002;20:613-614.
3. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358:1119-1123.
4. Liu C, Cheng J. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev. 2005;25:CD004434.
5. Akesson A, Scheja A, Lundin A, Wollheim FA. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum. 1994;37:729-735.
6. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655-2666.
7. van Laar JM, Farge D, Tyndall A. Autologous Stem cell Transplantation International Scleroderma (ASTIS) trial: hope on the horizon for patients with severe systemic sclerosis. Ann Rheum Dis. 2005;64:1515.
8. Akesson A, Wollheim FA. Organ manifestations in 100 patients with progressive systemic sclerosis: a comparison between the CREST syndrome and diffuse scleroderma. Br J Rheumatol. 1989;28:281-286.
9. Lundberg AC, Akesson A, Akesson B. Dietary intake and nutritional status in patients with systemic sclerosis. Ann Rheum Dis. 1992;51:1143-1148.
10. Exadaktylos A, Papagrigoriadis S. Chronic constipation - a lethal danger in patients with systemic scleroderma. Eur J Emerg Med. 2001;8:333-335.
11. Malandrini A, Selvi E, Villanova M, et al. Autonomic nervous system and smooth muscle cell involvement in systemic sclerosis: ultrastructural study of 3 cases. J Rheumatol. 2000;27:1203-1206.
12. Eaker EY, Kuldau JG, Verne GN, Ross SO, Sallustio JE. Myenteric neuronal antibodies in scleroderma: passive transfer evokes alterations in intestinal myoelectric activity in a rat model. J Lab Clin Med. 1999;133:551-556.
13. Cohen S, Fisher R, Lipshutz W, Turner R, Myers A, Schumacher R. The pathogenesis of esophageal dysfunction in scleroderma and Raynaud's disease. J Clin Invest. 1972;51:2663-2668.
14. Akesson A, Ekman R. Gastrointestinal regulatory peptides in systemic sclerosis. Arthritis Rheum. 1993;36:698-703.
15. Akesson A, Ekman R, Prytz H, Sundler F. Tissue concentrations of gastrointestinal regulatory peptides in the duodenal mucosa in systemic sclerosis. Clin Exp Rheumatol. 1998;16:141-148.
16. Sjolund K, Bartosik I, Lindberg G, Scheja A, Wildt M, Akesson A. Small intestinal manometry in patients with systemic sclerosis. Eur J Gastroenterol Hepatol. 2005;17:1205-1212.
17. Nikou GC, Toumpanakis C, Kataiari C, et al. Treatment of small intestinal disease in systemic sclerosis with octreotide: A prospective study in 7 patient. J Clin Rheumatol. 2007;13:119-123.
18. Ahmad N, Keith-Ferris J, Gooden E, Abell T. Making a case for domperidone in the treatment of gastrointestinal motility disorders. Curr Opin Pharmacol. 2006;6:571-576.
19. Drolet B, Rousseau G, Daleau P, Cardinal R, Turgeon J. Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation. 2000;102:1883-1885.
20. Tutuian R, Mainie I, Allan R, et al. Effects of a 5-HT(4) receptor agonist on oesophageal function and gastro-oesophageal reflux: studies using combined impedance-manometry and combined impedance-pH. Aliment Pharmacol Ther. 2006;24:155-162.
21. Tulassay Z. Somatostatin and the gastrointestinal tract. Scand J Gastroenterol Suppl. 1998;228:115-121.
22. Shulkes A. Somatostatin: physiology and clinical applications. Baillieres Clin Endocrinol Metab. 19948:215-236.
23. McKeage K, Cheer S, Wagstaff AJ. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs. 2003;63:2473-2499.
24. Malcolm A, Ellard K. Intestinal perforation associated with octreotide therapy in scleroderma. Am J Gastroenterol. 2001;96:3206-3208.
25. Athanasakis E, Chrysos E, Zoras OJ, Tsiaoussis J, Karkavitsas N, Xynos E. Octreotide enhances the accelerating effect of erythromycin on gastric emptying in healthy subjects. Aliment Pharmacol Ther. 2002;16:1563-1570.